LJUBLJANA (Slovenia), January 28 (SeeNews) – Slovenian pharmaceuticals producer Krka [LJE:KRKG] recorded a consolidated net profit of 286.6 million euro ($347.1 million) in 2020, up 17% on the year, the company said on Thursday, citing unaudited data.
Consolidated revenue increased to 1.535 billion euro from 1.493 billion euro in 2019, Krka said in a bourse filing.
The 2020 operating profit of the Krka group amounted to 388.7 million euro, up 42% year-on-year, while consolidated EBITDA amounted to 499.3 million euro, up 30% year-on-year.
The Krka group allocated 78 million euro to investments last year, of which 61 million euro to the controlling company.
Eastern Europe generated the highest sales within the group, of 517.2 million euro, or 33.8% of total sales. Sales in Eastern Europe rose 7% on the year in 2020.
Next came Central Europe, where sales revenue increased 1% to 341.5 million euro, or 22.3% of total sales. West Europe followed with sales of 341.1 million euro, also up 1% over 2019 and 22.3% of total.
Sales in Southeast Europe grew 4% to 199.4 million euro, whereas sales in the Overseas Markets segment decreased 6% to 45.7 million euro.
Sales in Slovenia decreased to 85.1 million euro, down 8% on the year. They contributed 5.6% of total Krka group sales.
The company's shares traded down 0.63% at 95.40 euro by 1301 CET on Thursday on the Ljubljana bourse.
($ = 0.825717 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here